Norm R. C. Campbell
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Norm R. C. Campbell has a total of 23 co-authors. Here are the top co-authors by number of shared publications:
Arun Chockalingam
NHLBI, Off Global Hlth, NIH, Bethesda, MD 20892 USA
2 shared publicationsDorothy Morris
Vancouver Isl Hlth Author, Canadian Council Cardiovasc Nurses, Victoria, BC, Canada
2 shared publicationsLawrence A. Leiter
Univ Toronto, Toronto, ON M5S 1A1, Canada
2 shared publicationsPierre Larochelle
Ctr Hosp Univ Montreal, Quebec City, PQ, Canada
2 shared publicationsRichard Ward
Univ Calgary, Dept Family Med, Calgary, AB T2N 1N4, Canada
2 shared publicationsSheldon Tobe
Univ Toronto, Toronto, ON M5S 1A1, Canada
2 shared publications
Latest Publications
- 1 September 2011
- Vol. 57 (9) , 997-1002
Hypertension in people with type 2 diabetes Update on pharmacologic management
Objective To summarize the evidence for the need to improve pharmacologic management of hypertension in people with type 2 diabetes and to provide expert advice on how blood pressure (BP) treatment can be improved in primary care. Sources of information Studies were obtained by performing a systematic review of the literature on hypertension and diabetes, from which management recommendations were developed, reviewed, and voted on by a group of experts selected by the Canadian Hypertension Education Program and the Canadian Diabetes Association; authors' expert opinions on optimal pharmacologic management were also considered during this process. Main message The pathogenesis of hypertension in patients with diabetes is complex, involving a range of biological and environmental factors and genetic predisposition; as a result, hypertension in people with diabetes incurs higher associated risks and adverse events. Mortality and morbidity are heightened in diabetes patients who do not achieve BP control (ie, a target value of less than 130/80 mm Hg). Large randomized controlled trials and meta-analyses of randomized controlled trials have shown that reducing BP pharmacologically is single-handedly the most effective way to reduce rates of death and disability in patients with diabetes, particularly associated cardiovascular risks. Often, combinations of 2 or more drugs (diuretics, angiotensin-converting enzyme inhibitors, beta-blockers, angiotensin receptor blockers, calcium channel blockers, spironolactone, etc) are required for pharmacotherapy to be effective, particularly for patients in whom BP is difficult to control. However, the health care costs associated with extensively lowering BP are substantially less than the costs associated with treating the complications that can be prevented by lowering BP. Conclusion Detecting and managing hypertension in people with diabetes is one of the most effective measures to prevent adverse events, and pharmacotherapy is one of the most effective ways to maintain target BP levels in primary care.
- 1 September 2011
- Vol. 57 (9) , 997-1002
Hypertension in people with type 2 diabetes Update on pharmacologic management
Objective To summarize the evidence for the need to improve pharmacologic management of hypertension in people with type 2 diabetes and to provide expert advice on how blood pressure (BP) treatment can be improved in primary care. Sources of information Studies were obtained by performing a systematic review of the literature on hypertension and diabetes, from which management recommendations were developed, reviewed, and voted on by a group of experts selected by the Canadian Hypertension Education Program and the Canadian Diabetes Association; authors' expert opinions on optimal pharmacologic management were also considered during this process. Main message The pathogenesis of hypertension in patients with diabetes is complex, involving a range of biological and environmental factors and genetic predisposition; as a result, hypertension in people with diabetes incurs higher associated risks and adverse events. Mortality and morbidity are heightened in diabetes patients who do not achieve BP control (ie, a target value of less than 130/80 mm Hg). Large randomized controlled trials and meta-analyses of randomized controlled trials have shown that reducing BP pharmacologically is single-handedly the most effective way to reduce rates of death and disability in patients with diabetes, particularly associated cardiovascular risks. Often, combinations of 2 or more drugs (diuretics, angiotensin-converting enzyme inhibitors, beta-blockers, angiotensin receptor blockers, calcium channel blockers, spironolactone, etc) are required for pharmacotherapy to be effective, particularly for patients in whom BP is difficult to control. However, the health care costs associated with extensively lowering BP are substantially less than the costs associated with treating the complications that can be prevented by lowering BP. Conclusion Detecting and managing hypertension in people with diabetes is one of the most effective measures to prevent adverse events, and pharmacotherapy is one of the most effective ways to maintain target BP levels in primary care.
- 1 May 2009
- Published by Elsevier in Canadian Journal of Cardiology
- Vol. 25 (5) , 299-302
Hypertension in diabetes: A call to action
- 1 May 2009
- Published by Elsevier in Canadian Journal of Cardiology
- Vol. 25 (5) , 299-302
Hypertension in diabetes: A call to action
- 1 February 2009
- Published by Wolters Kluwer Health in Hypertension
- Vol. 53 (2) , 128-134
Increases in Antihypertensive Prescriptions and Reductions in Cardiovascular Events in Canada
The Canadian Hypertension Education Program, an extensive professional education program to improve the management of hypertension, was started in 1999. There were very large increases in diagnosis and treatment of hypertension in the first 4 years after initiation of the program. The purpose of this study was to examine the association between the changes in antihypertensive therapy with changes in hospitalization and death from major hypertension-related cardiovascular diseases in Canada between 1992 and 2003. Using various national databases, Canadian standardized yearly mortality and hospitalization rates per 1000 for stroke, heart failure, and acute myocardial infarction were calculated for individuals aged ≥20 years and regressed against antihypertensive prescription rates. Changes in rates were examined in a time series analysis. There were significant reductions ( P P P P P P =0.018 for acute myocardial infarction) were associated with the increases in antihypertensive prescriptions. This study demonstrates that the reduction in cardiovascular death and hospitalization rates is associated with an increase in antihypertensive prescriptions and that it coincides with the introduction of the Canadian Hypertension Education Program. The Canadian Hypertension Education Program educational model for improving health care could be adopted by other countries with well-developed professional and scientific societies.
- 1 February 2009
- Published by Wolters Kluwer Health in Hypertension
- Vol. 53 (2) , 128-134
Increases in Antihypertensive Prescriptions and Reductions in Cardiovascular Events in Canada
The Canadian Hypertension Education Program, an extensive professional education program to improve the management of hypertension, was started in 1999. There were very large increases in diagnosis and treatment of hypertension in the first 4 years after initiation of the program. The purpose of this study was to examine the association between the changes in antihypertensive therapy with changes in hospitalization and death from major hypertension-related cardiovascular diseases in Canada between 1992 and 2003. Using various national databases, Canadian standardized yearly mortality and hospitalization rates per 1000 for stroke, heart failure, and acute myocardial infarction were calculated for individuals aged ≥20 years and regressed against antihypertensive prescription rates. Changes in rates were examined in a time series analysis. There were significant reductions ( P P P P P P =0.018 for acute myocardial infarction) were associated with the increases in antihypertensive prescriptions. This study demonstrates that the reduction in cardiovascular death and hospitalization rates is associated with an increase in antihypertensive prescriptions and that it coincides with the introduction of the Canadian Hypertension Education Program. The Canadian Hypertension Education Program educational model for improving health care could be adopted by other countries with well-developed professional and scientific societies.
- 1 May 2007
- Published by Elsevier in Canadian Journal of Cardiology
- Vol. 23 (6) , 437-443
Estimate of the benefits of a population-based reduction in dietary sodium additives on hypertension and its related health care costs in Canada
- 1 May 2007
- Published by Elsevier in Canadian Journal of Cardiology
- Vol. 23 (6) , 437-443
Estimate of the benefits of a population-based reduction in dietary sodium additives on hypertension and its related health care costs in Canada
- 1 May 2007
- Published by Elsevier in Canadian Journal of Cardiology
- Vol. 23 (7) , 557-560
Canada Chair in hypertension prevention and control: A pilot project
- 1 May 2007
- Published by Elsevier in Canadian Journal of Cardiology
- Vol. 23 (7) , 557-560
Canada Chair in hypertension prevention and control: A pilot project
- 1 May 2007
- Published by Elsevier in Canadian Journal of Cardiology
- Vol. 23 (7) , 561-565
Antihypertensive medication use by recently diagnosed hypertensive Canadians
- 1 May 2007
- Published by Elsevier in Canadian Journal of Cardiology
- Vol. 23 (7) , 561-565
Antihypertensive medication use by recently diagnosed hypertensive Canadians